JPMorgan analyst Sofie Peterzens raised the firm’s price target on Banco Santander (SAN) to EUR 6.60 from EUR 5.80 and keeps a Neutral rating on the shares. Published first on TheFly – the ...

Barclays analyst Paola Sabbione maintained a Buy rating on Banco BPM S.p.A. (0RLA – Research Report) today and set a price target of €9.50. The company’s shares closed yesterday at €8.86.

Lone Star owns 75% of Novo Banco, and Portugal’s government holds 25% through entities including the country’s Resolution Fund, which is run by the Bank of Portugal. Novo Banco is a long ...

LISBON, Feb 13 (Reuters) - Portugal's Novo Banco has begun preparations for an initial public offering (IPO) that could be one of the largest in Europe this year, tapping into a surge in ...

(Bloomberg) -- Novo Banco SA, a Portuguese lender that’s majority-owned by US private equity firm Lone Star, has selected banks to arrange an initial public offering, according to people familiar with ...

LISBON (Reuters) - U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco via an initial public offering, rather than seek a full ...

LISBON, Feb 12 (Reuters) - Portugal's banking resolution fund aims to sell its 13.54% stake in Novo Banco at the best possible price to maximise revenues, the fund's chief Luis Maximo dos Santos ...

Santander's Portuguese bank is not interested in buying Novo Banco, its CEO Pedro Castro Almeida said on Friday, as its ...

US private equity firm Lone Star has indicated to the Portuguese government its plans to sell a 25-30% stake in Novo Banco via an initial public offering (IPO), according to Portugal Finance ...

Portugal's banking resolution fund aims to sell its 13.54% stake in Novo Banco at the best possible price to maximise ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% jump in the Danish drugmaker’s share price in premarket trading.

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co-develop oral treatments for the red blood cell disorder and other ...